[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-associated-coagulopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-associated-coagulopathy":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100592359","observational-study-of-intranasal-ivig-in-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-patients-undergoing-medical-tourism-100592359",false,"NCT06992401","Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","An Observational Study Collecting Real-World Data on Intranasal IVIG Treatment in Long COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Immunodeficiency Engaged in International Medical Tourism","IVIG-LC","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)\n* Laboratory-confirmed immunodeficiency, including one or more of the following:\n* Low serum IgG and\u002For IgA\n* Specific antibody deficiency\n* Low pneumonia titers\n* Elevated inflammatory markers (e.g., CRP, cytokines)\n* No active infections at the time of enrollment (bacterial, viral, or fungal)\n* Negative for Lyme disease and NMDAR antibodies\n* Willingness to provide informed consent for data collection and use\n\nExclusion Criteria:\n\n* Current or recent active infection (e.g., viral, bacterial, or fungal)\n* Use of immunosuppressive therapy within the last 3 months\n* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded\n* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded\n* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded\n* Inability to comply with study assessments or procedures","ALL","18 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","12 Weeks","OBSERVATIONAL","This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.\n\nParticipants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.\n\nThe goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.",[27,28,29,30,31,32],"Post-Acute Sequelae of SARS-CoV-2 Infection","Long COVID","Long COVID Fatigue","Long COVID Syndrome","COVID 19 Associated Coagulopathy","COVID-19 Vaccination",[34,35,36,37,38,39,40,41,42,43,44,45],"Intranasal IVIG","Real-world data","Medical tourism","Long COVID fatigue","Cytokine panel","Immunoglobulin therapy","Brain fog","Chronic inflammation","Real-world evidence","Global health","Post-viral syndrome","Immune recovery","NOT_YET_RECRUITING","2025-11-24",{"date":49,"type":50},"2025-12-02","ACTUAL",{"date":52,"type":22},"2026-08-01",{"date":54,"type":22},"2029-07-15",{"name":56,"class":57},"Tamara C Tamas","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100543391","phase-1-a-study-of-the-efficacy-of-troxerutin-in-preventing-thrombotic-events-in-covid-19-patients-100543391","NCT06355258","A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients","Inclusion Criteria:\n\nAs long as the patient meets all of the following conditions, adult patients aged 18 and above are eligible for admission:\n\n► COVID-19 patients, defined as: positive RT-PCR (upper respiratory tract or lower respiratory tract) for SARS-CoV-2.\n\nMild COVID-19 patients are defined as:\n\nSymptomatic patients meeting the case definition for COVID-19 without evidence of hypoxia or pneumonia. Common symptoms include fever, cough, fatigue, anorexia, dyspnea, and myalgia. Other nonspecific symptoms include sore throat, nasal congestion, headache, diarrhea, nausea\u002Fvomiting, and loss of smell\u002Ftaste.\n\nSevere COVID-19 patients are defined as:\n\nAdolescents or adults with clinical signs of pneumonia (i.e., fever, cough, dyspnea, tachypnea) plus one of the following:\n\n1. Respiratory rate ≥30 breaths\u002Fmin\n2. Severe respiratory distress\n3. Oxygen saturation (SpO₂) ≤90% in room air\n4. Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (\\>50%) within 24 to 48 hours.\n\n   * Written informed consent provided according to Chinese law (by the patient, legal guardian, or deferred consent in emergencies).\n\nExclusion Criteria:\n\nPatients with any of the following conditions will be excluded from the study:\n\n* Pregnant or lactating women.\n* Postpartum (within 6 weeks).\n* Extreme weight (100 kilograms).\n* Clinical need for heparin therapy.\n* Bleeding related to coagulation disorders, acute clinically significant bleeding, active gastrointestinal ulcers, or any organic lesions with high bleeding risk.\n* Platelet count \\\u003C50 x 10\\^9\u002FL.\n* Surgery within the last 15 days, or within 24 hours after spinal or epidural anesthesia.\n* History of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, acute infective endocarditis.\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n* Iodine allergy.\n* Long-term use of oxygen supplementation.\n* Moribund patients or those expected to die during the current hospitalization due to underlying disease.\n* Patients deprived of freedom and those undergoing institutional psychiatric care.\n* Ward of the state or under guardianship.\n* Participation in other anticoagulant intervention studies.",{"count":65,"type":22},80,"INTERVENTIONAL",[68],"PHASE1","The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:\n\n* Does troxerutin lower the number of thrombotic events in participants?\n* What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.\n\nParticipants will:\n\n* Take troxerutin or a placebo every day for 7 days.\n* Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests\n* Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia",[31],"RECRUITING","2024-11-10",{"date":74,"type":50},"2024-11-12",{"date":76,"type":50},"2023-12-15",{"date":78,"type":22},"2025-03",{"name":80,"class":57},"Westlake University",1]